oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2018-17-6-114-122oncotomsk-911Research ArticleОБЗОРЫREVIEWSКлинико-фармакологические особенности лекарственных взаимодействий опиоидов у пациентов с хроническим болевым синдромом в практической онкологииClinico-pharmacological characteristics of opioid drug-drug interactions in cancer patients with chronic pain syndromehttps://orcid.org/0000-0002-1779-9125БоброваО. П.BobrovaO. P.

Боброва Ольга Петровна - кандидат медицинских наук, доцент кафедры фармакологии и фармацевтического консультирования с курсом ПО, КГМУ им. проф. В.Ф. Войно-Ясенецкого; врач-клинический фармаколог ККОД им. А.И. Крыжановского.

660022, Красноярск, ул. Партизана Железняка; 660133, г Красноярск, ул. 1-я Смоленская, 16

Olga P. Bobrova - MD, PhD, Associated Professor of the Department of Pharmacology and Pharmaceutical Consulting and Postgraduate Education, KSMU named after Professor V.F. Voyno-Yasenetsky; Clinical Pharmacologis KRCOC named after A.I. Kryzhanovsky

16, Smolenskaya Street, 660133-Krasnoyarsk

bop_351971@mail.ruhttps://orcid.org/0000-0002-2840-837XШнайдерН. А.ShnayderN. A.

Шнайдер Наталья Алексеевна - доктор медицинских наук, профессор, ведущий научный сотрудник отделения персонализированной психиатрии и неврологии.

Санкт-Петербург, 192019, ул. Бехтерева, 3

SPIN-код: 6517-0279, ResearcherlD (WOS): M-7084-2014

Natalya A. Shnayder - MD, Professor, Leading Researcher

3, Bekhterev Street, 192019-St. Petersburg

ResearcherID (WOS): M-7084-2014

naschnaider@yandex.ruhttps://orcid.org/0000-0002-6348-6867ЗыряновС. К.ZyryanovS. K.

Зырянов Сергей Кенсаринович - доктор медицинских наук, профессор, заведующий кафедрой общей и клинической фармакологии.

117198,  Москва, ул. Миклухо-Маклая, 6

Sergei K. Zyryanov, MD, Professor, Head of the Department of General and Clinical Pharmacology.

6, Miklukho-Maklay Street, 117198-Moscow

sergey.k.zyryanov@gmail.comhttps://orcid.org/0000-0003-0075-215XДыхноЮ. А.DyhnoYu. A.

Дыхно Юрий Александрович, доктор медицинских наук, профессор кафедры онкологии и лучевой терапии с курсом ПО, КГМУ им. проф. В.Ф. Войно-Ясенецкого.

660022, Красноярск, ул. Партизана Железняка; 660133,  Красноярск, ул. 1-я Смоленская, 16

SPIN-код: 2505-2322, ResearcherlD (WOS): O-8028-2015

Yuri A. Dykhno - MD, Professor, Department of Oncology and Radiation Therapy.

ResearcherID (WOS): O-8028-2015

16, Smolenskaya Street, 660133-Krasnoyarsk

Dykhno_yury@mail.ruhttps://orcid.org/0000-0002-8493-0058ПетроваМ. М.PetrovaM. M.

Петрова Марина Михайловна - доктор медицинских наук, профессор, заведующая кафедрой поликлинической терапии, семейной медицины и ЗОЖ с курсом ПО.

660022, Красноярск, ул. Партизана Железняка

Marina M. Petrova - MD, Professor, Head of the Department of Ambulance Care.

16, Smolenskaya Street, 660133-Krasnoyarsk

ResearcherID (WOS): L-5623-2014

stk99@yandex.ruhttps://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

Насырова Регина Фаритовна - доктор медицинских наук, руководитель отделения персонализированной психиатрии и неврологии, ведущий научный сотрудник.

Санкт-Петербург, 192019, ул. Бехтерева, 3

SPIN-код: 3799-0099, ResearcherID (WOS): B-1259-2014, Author ID (Scopus): 15769218400

Regina F. Nasyrova - MD, DSc, Head of the Department of Personalized Psychiatry and Neurology, Leading Researcher, V.M. Bekhterev NMRCPN RFMH.

3, Bekhterev Street, 192019-St. Petersburg

ResearcherID (WOS): B-1259-2014

reginaf@bekhterev.ruФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России; КГБУЗ Красноярский краевой клинический онкологический диспансер им. А.И. КрыжановскогоРоссияKrasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. KryzhanovskyRussian FederationФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава РоссииРоссияV.M. Bekhterev National Medical Research Center of Psychiatry and Neurology of the Health Ministry of the Russian FederationRussian FederationФГАОУ ВО Российский университет дружбы народовРоссияPeoples' Friendship University of RussiaRussian FederationФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава РоссииРоссияKrasnoyarsk Regional Clinical Oncology Dispensary named after A.I. KryzhanovskyRussian Federation201801012019176114122Copyright © Боброва О.П., Шнайдер Н.А., Зырянов С.К., Дыхно Ю.А., Петрова М.М., Насырова Р.Ф., 20192019Боброва О.П., Шнайдер Н.А., Зырянов С.К., Дыхно Ю.А., Петрова М.М., Насырова Р.Ф.Bobrova O.P., Shnayder N.A., Zyryanov S.K., Dyhno Y.A., Petrova M.M., Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/911

Цель исследования - анализ отечественной и зарубежной литературы о влиянии лекарственных взаимодействий опиоидов на индивидуальный выбор схем анальгетической терапии в онкологии.

Материал и методы

Материал и методы. Поиск источников производился в системах PubMed, Scopus, Web of Science, E-library.

Результаты

Результаты. В обзоре показано клиническое значение фармакокинетических взаимодействий опиоидов с другими лекарственными средствами в рамках анальгетической терапии хронического болевого синдрома в онкологии. Освещаются вопросы индивидуального выбора анальгетиков разных групп в условиях коморбидности и сопутствующей лекарственной терапии с целью обеспечения эффективности/безопасности стратегии лечения, влияющей на качество жизни пациентов со злокачественными новообразованиями.

Заключение

Заключение. Комплексная оценка факторов у пациентов, получающих опиоидные анальгетики, является предиктором эффективной и безопасной анальгетической терапии.

The aim of the review was to analyze published studies on the impact of opioid drug-drug interactions on the choice of analgesic therapy regimens.

Material and methods

Material and methods. A systematic literature search was conducted using PubMed, Scopus, Web of Science, and E-library databases.

Results

Results. The review showed a clinical significance of pharmacokinetic interactions of opioids with other drugs in cancer pain treatment. The problems of individual choice of analgesics from different groups under conditions of co-morbidity and concomitant medication were discussed to ensure the effectiveness/safety of the treatment strategy affecting the quality of life of cancer patients.

Conclusion

Conclusion. A comprehensive assessment of factors in patients receiving opioid analgesics is a predictor of effective and safe analgesic therapy.

лекарственные взаимодействияопиоидыхронический болевой синдромкоморбидностьзлокачественные новообразованияанальгетикилекарственная терапияантидепрессантытамоксифенантимикотикиdrug interactionsopioidschronic pain syndromecomorbiditymalignant neoplasmsanalgesicsdrug therapyantidepressantstamoxifenantimycoticsReferencesSummersK.H., Puenpatom RA., RajanN., Ben-JosephR., OhsfeldtR. Economic impact of potential drug - drug interactions in opioid analgesics. J Med Econ. 2011; 14 (4): 390-96. doi: 10.3111/13696998.2011.SummersK.H., Puenpatom RA., RajanN., Ben-JosephR., OhsfeldtR. Economic impact of potential drug - drug interactions in opioid analgesics. J Med Econ. 2011; 14 (4): 390-96. doi: 10.3111/13696998.2011.van Leeuwen R.W.F., SwartE.L., Boven E., Boom F.A., Schuiten-makerM.G., Hugtenburg J.G. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011 Oct; 22 (10): 2334-41. doi: 10.1093/annonc/mdq761.van Leeuwen R.W.F., SwartE.L., Boven E., Boom F.A., Schuiten-makerM.G., Hugtenburg J.G. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011 Oct; 22 (10): 2334-41. doi: 10.1093/annonc/mdq761.Buajordet I., Ebbesen J., Erikssen J., Br0rs O., Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001; 250: 327-341.Buajordet I., Ebbesen J., Erikssen J., Br0rs O., Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001; 250: 327-341.Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9-29. doi: 10.3322/caac.21208.Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9-29. doi: 10.3322/caac.21208.Kapur B.M., Lala P.K., Shaw J.L. Pharmacogenetics of chronic pain management. Clin Biochem. 2014 Sep; 47 (13-14): 1169-87. doi: 10.1016/j.clinbiochem.2014.05.065.Kapur B.M., Lala P.K., Shaw J.L. Pharmacogenetics of chronic pain management. Clin Biochem. 2014 Sep; 47 (13-14): 1169-87. doi: 10.1016/j.clinbiochem.2014.05.065.Overholser B.R., Foster D.R. Opioid pharmacokinetic drug - drug interactions. Am J Manag Care. 2011 Sep;17 Suppl 11: S276-87.Overholser B.R., Foster D.R. Opioid pharmacokinetic drug - drug interactions. Am J Manag Care. 2011 Sep;17 Suppl 11: S276-87.CavallariL.H., Jeong H., Bress A. Role of cytochrome P450 geno-typeinthe steps toward personalized drug therapy. Pharmgenomics Pers Med. 2011; 4: 123-36. doi: 10.2147/PGPM.S15497.CavallariL.H., Jeong H., Bress A. Role of cytochrome P450 geno-typeinthe steps toward personalized drug therapy. Pharmgenomics Pers Med. 2011; 4: 123-36. doi: 10.2147/PGPM.S15497.Gudin J. Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec; 44 (6 Suppl): S4-14. doi: 10.1016/j.jpainsymman.2012.08.013.Gudin J. Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec; 44 (6 Suppl): S4-14. doi: 10.1016/j.jpainsymman.2012.08.013.Mercadante S., Porzio G., AielliF, Adile C., VernaL., Ficorella C., Giarratano A., Casuccio A. Opioid switching from and to tapen-tadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013 Jun; 29 (6): 661-6. doi: 10.1185/03007995.2013.791617.Mercadante S., Porzio G., AielliF, Adile C., VernaL., Ficorella C., Giarratano A., Casuccio A. Opioid switching from and to tapen-tadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013 Jun; 29 (6): 661-6. doi: 10.1185/03007995.2013.791617.Боброва О.П., Дыхно Ю.А., Шнайдер НА., Петрова М.М., Зырянов С.К. Фармакокинетические и фармакогенетические аспекты персонализированной анальгетической терапии фентанилом ТТС в онкологии. Сибирский онкологический журнал. 2018; 17 (3): 94-100. doi: 10.21294/1814-4861-2018-17-3-94-100.Bobrova O.P., Dyhno YA., Shnayder NA., PetrovaM.M., Zyryanov S.K. Pharmacokinetic and pharmacogenetic aspects of personalized analgetic therapy with fentanil TTS in clinical oncology. Siberian journal of oncology. 2018; 17 (3): 94-100. (in Russian). doi: 10.21294/1814-4861-2018-17-3-94-100.BernardSA., BrueraE. Drug interactions in palliative care. J. Clin. Oncol. 2000; 18 (8): 1780-1799. doi: 10.1200/JCO.2000.18.8.1780BernardSA., BrueraE. Drug interactions in palliative care. J. Clin. Oncol. 2000; 18 (8): 1780-1799. doi: 10.1200/JCO.2000.18.8.1780SmithH.S. Opioid metabolism. Mayo Clin Proc. 2009 Jul; 84 (7): 613-24. doi: 10.1016/S0025-6196(11)60750-7.SmithH.S. Opioid metabolism. Mayo Clin Proc. 2009 Jul; 84 (7): 613-24. doi: 10.1016/S0025-6196(11)60750-7.Samer C.F., Lorenzini K. Ing, Rollason V, Daali Y., Desmeules JA. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther. 2013 Jun; 17 (3): 165-84. doi: 10.1007/s40291-013-0028-5.Samer C.F., Lorenzini K. Ing, Rollason V, Daali Y., Desmeules JA. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther. 2013 Jun; 17 (3): 165-84. doi: 10.1007/s40291-013-0028-5.MadadiP.,HildebrandsD., GongI.Y., Schwarz U.I., Ciszkowski C., Ross C.J., Sistonen J., Carleton B.C., Hayden M.R., Lauwers A.E., Koren G. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. 2010 Oct; 126 (4): e986-9. doi: 10.1542/peds.2009-1907.MadadiP.,HildebrandsD., GongI.Y., Schwarz U.I., Ciszkowski C., Ross C.J., Sistonen J., Carleton B.C., Hayden M.R., Lauwers A.E., Koren G. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. 2010 Oct; 126 (4): e986-9. doi: 10.1542/peds.2009-1907.Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., RossierM.F., Hochstrasser D., Dayer P., J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., RossierM.F., Hochstrasser D., Dayer P., J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352: 2211-21. doi:10.1056/NEJMra032424.Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352: 2211-21. doi:10.1056/NEJMra032424.DonatoM.T., MonteroS., CastellJ.V, Gomez-LechonM.J.,Lahoz A. Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem. 2010 Mar; 396 (6): 2251-63. doi: 10.1007/s00216-009-3441-1.DonatoM.T., MonteroS., CastellJ.V, Gomez-LechonM.J.,Lahoz A. Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem. 2010 Mar; 396 (6): 2251-63. doi: 10.1007/s00216-009-3441-1.Chen C., Upward J., Arumugham T., Stier B., Davy M. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clin Ther. 2015 Feb 1; 37 (2): 349-57. doi: 10.1016/j.clinthera.2014.10.015.Chen C., Upward J., Arumugham T., Stier B., Davy M. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clin Ther. 2015 Feb 1; 37 (2): 349-57. doi: 10.1016/j.clinthera.2014.10.015.Фурса О.О., Козловский В.Л. Роль цитохром p450-зависимой биотрансформации в метаболизме антипсихотиков. Социальная и клиническая психиатрия. 2013; 23 (4): 51-55.Foursa O.O., Kozlovsky VL. The role of cytochrome p450-dependent biotransformation in metabolism of antipsychotics. Russian Society of Psychiatrists. 2013; 23 (4): 51-55. (in Russian).Tekes K., Hashemi F, Szegi P, Sotonyi P, Laufer R., Kalasz H. Prodrugs and active metabolites among antidepressive compounds. Neu-ropsychopharmacol Hung. 2011 Jun; 13 (2): 103-10.Tekes K., Hashemi F, Szegi P, Sotonyi P, Laufer R., Kalasz H. Prodrugs and active metabolites among antidepressive compounds. Neu-ropsychopharmacol Hung. 2011 Jun; 13 (2): 103-10.Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000 Jan; 40 (1): 58-66.Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000 Jan; 40 (1): 58-66.Parker R.B., Soberman J.E. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011 Jul; 31 (7): 630-41. doi: 10.1592/phco.31.7.630.Parker R.B., Soberman J.E. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011 Jul; 31 (7): 630-41. doi: 10.1592/phco.31.7.630.Donato M.T., Hallifax D., Picazo L., Castell J.V, Houston J.B., Gomez-Lechon M.J., Lahoz A. Metabolite formation kineticsand intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam in adenoviral P450 transfected HepG2 cells, and comparison with hepatocytes and in vivo. Drug Metab Dispos. 2010 Sep; 38 (9): 1449-55. doi: 10.1124/dmd.110.033605.Donato M.T., Hallifax D., Picazo L., Castell J.V, Houston J.B., Gomez-Lechon M.J., Lahoz A. Metabolite formation kineticsand intrinsic clearance of phenacetin, tolbutamide, alprazolam and midazolam in adenoviral P450 transfected HepG2 cells, and comparison with hepatocytes and in vivo. Drug Metab Dispos. 2010 Sep; 38 (9): 1449-55. doi: 10.1124/dmd.110.033605.Pergolizzi J.VJr., Ma L., Foster D.R., Overholser B.R., Sowin-ski K.M., Taylor R.Jr., Summers K.H. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Pharm. 2014; 20 (5): 467-76. doi: 10.18553/jmcp.2014.20.5.467.Pergolizzi J.VJr., Ma L., Foster D.R., Overholser B.R., Sowin-ski K.M., Taylor R.Jr., Summers K.H. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Pharm. 2014; 20 (5): 467-76. doi: 10.18553/jmcp.2014.20.5.467.FengX.Q., Zhu L.L., Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017; 10: 1225-39. doi: 10.2147/JPR.S138698.ecollection 2017.FengX.Q., Zhu L.L., Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017; 10: 1225-39. doi: 10.2147/JPR.S138698.ecollection 2017.HanleyM.J., CancalonP, Widmer W.W., GreenblattDJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011 Mar; 7 (3): 267-86. doi: 10.1517/17425255.2011.553189.HanleyM.J., CancalonP, Widmer W.W., GreenblattDJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011 Mar; 7 (3): 267-86. doi: 10.1517/17425255.2011.553189.Madlensky L., Natarajan L., Tchu S., Pu M., Mortimer J., Flatt S. W., Nikoloff DM., Hillman G., Fontecha M.R., Lawrence H.J., Parker B.A., Wu A.H., Pierce J.P. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May; 89 (5): 718-25. doi: 10.1038/clpt.2011.32.Madlensky L., Natarajan L., Tchu S., Pu M., Mortimer J., Flatt S. W., Nikoloff DM., Hillman G., Fontecha M.R., Lawrence H.J., Parker B.A., Wu A.H., Pierce J.P. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May; 89 (5): 718-25. doi: 10.1038/clpt.2011.32.Fihlman M., Hemmila T., Hagelberg N.M., Kuusniemi K., Back-man J.T., Laitila J., Laine K., Neuvonen P.J., Olkkola K.T., Saari T. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 2016; 72 (11): 1363-1371. doi: 10.1007/ s00228-016-2109-y.Fihlman M., Hemmila T., Hagelberg N.M., Kuusniemi K., Back-man J.T., Laitila J., Laine K., Neuvonen P.J., Olkkola K.T., Saari T. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 2016; 72 (11): 1363-1371. doi: 10.1007/ s00228-016-2109-y.Ziesenitz VC., Konig S.K., Mahlke N.S., Skopp G., Haefeli W.E., Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015; 55 (6): 708-717. doi: 10.1002/jcph.469.Ziesenitz VC., Konig S.K., Mahlke N.S., Skopp G., Haefeli W.E., Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015; 55 (6): 708-717. doi: 10.1002/jcph.469.Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., Rossier M.F., Hochstrasser D., Dayer P, Desmeules J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., RebsamenM.C., Rossier M.F., Hochstrasser D., Dayer P, Desmeules J.A. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun; 160 (4): 907-18. doi: 10.1111/j.1476-5381.2010.00673.x.Trobec K., Kerec Kos M., von Haehling S., Springer J., Anker S.D., Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013 Nov 8; 8 (П): e79603. doi: 10.1371/journal.pone.0079603.Trobec K., Kerec Kos M., von Haehling S., Springer J., Anker S.D., Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013 Nov 8; 8 (П): e79603. doi: 10.1371/journal.pone.0079603.

The authors declare that there are no conflicts of interest present.